CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

Rhea-AI Summary

CASI Pharmaceuticals (Nasdaq: CASI) will host a conference call on May 12, 2022, at 8:00 a.m. EST to discuss its first-quarter 2022 financial results. The call will include updates from the Chairman & CEO on business developments and milestones. Interested parties can join the call by dialing the provided numbers, and a replay will be available afterwards. CASI focuses on developing innovative therapeutics in hematology oncology, particularly in the China market, through its wholly-owned subsidiary in Beijing.

Positive

• CASI Pharmaceuticals is focused on the promising hematology oncology sector.
• The company has established a strong sales and marketing team of over 100 specialists in China.

Negative

• None.

ROCKVILLE, Md. and BEIJING, May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the first quarter of 2022, at 8:00 a.m. EST on Thursday, May 12^th, 2022.

On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (international) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call. Confirmation #10165613.

This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and enter 2360248 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 ir@casipharmaceuticals.com

INVESTOR CONTACT: Xuan Yang Solebury Trout 646.378.2975 xyang@soleburytrout.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-first-quarter-2022-financial-results-and-host-conference-call-may-12-2022-301536848.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

When is CASI Pharmaceuticals' first quarter 2022 financial results conference call?

The conference call is scheduled for May 12, 2022, at 8:00 a.m. EST.

How can I access the conference call for CASI Pharmaceuticals?

You can access the call by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (international).

What company updates will be discussed during CASI Pharmaceuticals' conference call?

The Chairman & CEO will provide updates on the company's business and upcoming milestones.

Where is CASI Pharmaceuticals focusing its business operations?

CASI Pharmaceuticals aims to develop and commercialize innovative therapeutics in the China market.